Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech bought 35,000 shares of the business’s stock in a transaction dated Wednesday, May 17th. The shares were bought at an average price of $33.44 per share, with a total value of $1,170,400.00. Following the purchase, the insider now owns 4,890,799 shares in the company, valued at approximately $163,548,318.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of Radius Health Inc (NASDAQ:RDUS) traded down 0.20% during mid-day trading on Friday, reaching $34.93. 798,738 shares of the company’s stock traded hands. The company’s market cap is $1.52 billion. The firm has a 50-day moving average of $36.57 and a 200 day moving average of $41.96. Radius Health Inc has a 12-month low of $31.58 and a 12-month high of $59.88.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by $0.14. During the same quarter last year, the firm earned ($0.94) EPS. Equities analysts forecast that Radius Health Inc will post ($4.41) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Mideast Time and is the property of of Mideast Time. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.mideasttime.com/radius-health-inc-rdus-major-shareholder-growth-n-v-biotech-purchases-35000-shares/1708861.html.
Large investors have recently added to or reduced their stakes in the stock. Sei Investments Co. increased its stake in shares of Radius Health by 17.8% in the third quarter. Sei Investments Co. now owns 2,082 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 314 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of Radius Health during the first quarter worth about $105,000. FNY Partners Fund LP purchased a new stake in shares of Radius Health during the fourth quarter worth about $160,000. Envestnet Asset Management Inc. increased its stake in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 46 shares during the last quarter. Finally, New England Private Wealth Advisors LLC purchased a new stake in shares of Radius Health during the third quarter worth about $270,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently issued reports on RDUS. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, February 28th. Maxim Group restated a “sell” rating and set a $24.00 target price on shares of Radius Health in a research note on Friday, February 24th. Cantor Fitzgerald set a $65.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Saturday, February 25th. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research note on Saturday, February 25th. Finally, Jefferies Group LLC restated a “hold” rating and set a $40.00 target price on shares of Radius Health in a research note on Friday, February 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $56.83.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.
Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.